Elucidating Multidimensional Kinase Signaling Regulation: The Precision of p90RSK Recombinant Rabbit Monoclonal Antibodies

Concept

p90 ribosomal S6 kinase (p90RSK), a conserved serine/threonine kinase of the AGC family, is a core nodal effector of the Ras-MAPK signaling pathway—one of the most critical cellular regulatory networks governing proliferation, survival, differentiation, and metabolic homeostasis. Endowed with two functionally distinct kinase domains (an N-terminal domain for substrate phosphorylation and a C-terminal domain for auto-regulation), p90RSK exerts its biological functions by phosphorylating a diverse array of cytoplasmic and nuclear substrates, including transcription factors, cell cycle regulators, and epigenetic modifiers. p90RSK recombinant rabbit monoclonal antibodies are high-precision immunological reagents engineered via advanced recombinant technology to recognize p90RSK (total protein or phosphorylated active forms) with exceptional specificity, affinity, and batch consistency. These antibodies enable the precise detection, subcellular localization, and functional analysis of p90RSK across diverse experimental systems, making them an indispensable tool for unraveling the multidimensional regulatory mechanisms of p90RSK kinase signaling in both physiological and pathological states.

Research Frontier

The Ras-MAPK signaling pathway and its downstream effector p90RSK remain a defining research hotspot in molecular cell biology, oncology, and neurobiology, with research frontiers shifting toward the multidimensional dissection of kinase signaling regulation—including spatiotemporal dynamics, post-translational modification crosstalk, and pathological reprogramming. Current advancements in p90RSK recombinant rabbit monoclonal antibody development focus on three core directions: epitope engineering for modification and conformation-specific recognition, validation for high-resolution spatiotemporal signaling analysis, and adaptation for translational research and drug development.

Cutting-edge antibody design strategies are refining the targeting of conserved and modification-specific epitopes of p90RSK (e.g., Thr359/Ser380 phosphorylation sites) to distinguish between total protein and activated kinase forms, while leveraging the unique antibody maturation mechanism of the rabbit immune system to generate reagents that recognize native conformational epitopes. Concurrently, these antibodies are being validated for use in high-resolution imaging and single-cell analysis techniques, enabling the visualization of p90RSK’s nucleocytoplasmic shuttling dynamics and signaling activity in heterogeneous cell populations. Additionally, the development of p90RSK recombinant rabbit monoclonal antibodies with validated performance in clinical tissue samples is driving their translation to oncology and neurobiology research, where they serve as tools for biomarker discovery and drug target validation.

Research Significance

p90RSK recombinant rabbit monoclonal antibodies hold profound scientific and translational significance, acting as a precision tool for dissecting the complex multidimensional regulation of kinase signaling and supporting breakthroughs in basic research, disease mechanism exploration, and anti-cancer drug development.

In basic molecular signaling research, these antibodies enable the precise characterization of p90RSK’s multidimensional regulatory features—including its spatiotemporal activation dynamics, nucleocytoplasmic shuttling, post-translational modification status, and protein-protein interaction networks. This knowledge is critical for unraveling how p90RSK integrates upstream Ras-MAPK signals to regulate downstream cellular processes, and for understanding the feedback and crosstalk mechanisms that govern kinase signaling homeostasis.

In disease mechanism research, aberrant p90RSK activation is a hallmark of numerous human pathologies, including breast, lung, and colorectal cancers, as well as certain neurological disorders. p90RSK recombinant rabbit monoclonal antibodies enable the detection of p90RSK expression and activation states in disease models and clinical samples, facilitating the identification of correlations between p90RSK signaling dysregulation and disease progression, drug resistance, and pathological phenotypes. They also provide a tool for elucidating the molecular mechanisms by which p90RSK drives disease, such as hormone therapy resistance in breast cancer and EGFR-TKI resistance in lung cancer.

In translational drug development, p90RSK is a promising therapeutic target for cancer and other diseases, and p90RSK recombinant rabbit monoclonal antibodies are indispensable for evaluating the efficacy and specificity of p90RSK-targeted inhibitors. They enable the quantitative assessment of target engagement (e.g., inhibition of p90RSK phosphorylation) in cell-based, in vivo, and organoid models, and help identify compensatory signaling mechanisms that drive drug resistance—critical insights for optimizing inhibitor design and developing combination therapy strategies.

Related Mechanism and Product Application

p90RSK: A Critical Nodal Kinase in Ras-MAPK Signaling Cascades

p90RSK occupies a central position in the Ras-MAPK signaling cascade, acting as a key downstream effector that translates upstream mitogenic and stress signals into functional cellular responses. Its unique structural and functional features make it a critical regulatory node:

1. Dual kinase domain architecture: The N-terminal kinase domain (NTKD) mediates the phosphorylation of a diverse range of cytoplasmic and nuclear substrates, while the C-terminal kinase domain (CTKD) auto-regulates p90RSK activity via intramolecular interactions and ERK-mediated phosphorylation at key sites (Thr359/Ser380).
2. Broad substrate repertoire: p90RSK phosphorylates transcription factors (CREB, c-Fos), ribosomal proteins, cell cycle regulators, and epigenetic modifiers, linking Ras-MAPK signaling to gene expression, protein synthesis, cell cycle progression, and epigenetic regulation.
3. Dynamic spatiotemporal regulation: In resting cells, p90RSK localizes primarily to the cytoplasm; upon Ras-MAPK activation, it undergoes phosphorylation and translocates to the nucleus to phosphorylate nuclear substrates, enabling the spatial segregation of its signaling functions.
4. Pathological dysregulation: Constitutive p90RSK activation—driven by Ras-MAPK pathway mutations or upstream signaling aberrations—contributes to uncontrolled cell proliferation, survival, and drug resistance in cancer, making it a key therapeutic target.

The multidimensional regulation of p90RSK (structural, post-translational, spatiotemporal) demands precision detection tools, and p90RSK recombinant rabbit monoclonal antibodies are engineered to meet this critical need.

Key Structural Considerations for p90RSK Recombinant Rabbit Monoclonal Antibody Design

The molecular complexity and dynamic regulation of p90RSK impose stringent requirements on the design of recombinant rabbit monoclonal antibodies, with four core structural and functional considerations shaping reagent development for multidimensional signaling analysis:

1. Total vs. phosphorylation-specific recognition: Antibodies targeting total p90RSK recognize conserved epitopes in the kinase domain (shared by all forms) and are used for quantifying overall protein expression and immunoprecipitation. Phosphorylation-specific antibodies target ERK-mediated activation sites (Thr359, Ser380) and enable the detection of p90RSK’s activated state—the key readout of Ras-MAPK signaling activity.
2. Coverage of diverse structural domains: Immunogens are designed to cover the NTKD, CTKD, and linker region of p90RSK, enriching antibody clones that recognize distinct structural features and enabling the analysis of intramolecular domain interactions that regulate kinase activity.
3. Recognition of conformational and modified epitopes: Leveraging the rabbit immune system’s unique ability to generate antibodies against conformational and post-translationally modified epitopes, the antibodies recognize native p90RSK conformations and modified forms, ensuring reliable detection in physiological conditions.
4. Cross-reactivity for subtype and species detection: The antibodies are engineered to recognize all major p90RSK subtypes (RSK1-4) via conserved domain targeting, and exhibit cross-species reactivity (human, mouse, rat), enabling comprehensive p90RSK family signaling analysis across diverse experimental models.

Unraveling Ras-MAPK Signaling Pathway Regulation

p90RSK recombinant rabbit monoclonal antibodies are powerful tools for dissecting the multidimensional regulation of the Ras-MAPK signaling pathway, with key applications in core signaling research techniques:

• Western Blot for quantitative activation analysis: The antibodies enable the simultaneous quantification of total p90RSK and its phosphorylated active forms, allowing researchers to generate dynamic activation curves under different cellular stimuli (e.g., growth factor treatment). By analyzing these curves, the intensity, duration, and feedback regulation of upstream ERK signaling can be inferred—uncovering key features of Ras-MAPK pathway dynamics.
• Immunofluorescence for spatiotemporal localization: The antibodies reveal the nucleocytoplasmic shuttling dynamics of p90RSK, a critical aspect of its multidimensional regulation. They visualize the translocation of activated p90RSK from the cytoplasm to the nucleus upon stimulation, and enable the mapping of the subcellular distribution of phosphorylated p90RSK—providing direct evidence for its nucleocytoplasmic transport mechanisms and spatial signaling functions.
• Immunoprecipitation for functional complex analysis: Combined with kinase activity assays, IP using p90RSK recombinant rabbit monoclonal antibodies enriches endogenous p90RSK protein complexes from cell lysates, enabling the detection of the kinase’s substrate phosphorylation capacity and the identification of interacting proteins that modulate its activity—unraveling the protein interaction networks that govern p90RSK signaling.

Deciphering Disease Mechanisms in Cancer and Neurobiology

p90RSK recombinant rabbit monoclonal antibodies are indispensable for elucidating the role of p90RSK signaling dysregulation in disease pathogenesis, with transformative applications in oncology and neurobiology research:

• Oncology research and drug resistance mechanisms: In breast cancer, the antibodies detect p90RSK-mediated phosphorylation of estrogen receptors and cyclins, elucidating the molecular basis of hormone therapy resistance. In lung cancer, they identify correlations between p90RSK activation, EGFR mutation status, and TKI resistance, and reveal the signaling network reprogramming that drives resistant phenotypes. Immunohistochemical staining with the antibodies also correlates p90RSK expression/activation levels with tumor clinicopathological parameters (e.g., stage, grade, prognosis), validating p90RSK as a cancer biomarker.
• Neurological disease research: In neurobiology, the antibodies detect p90RSK expression and distribution in different brain regions and neuronal subpopulations via brain tissue section staining, providing an anatomical basis for understanding its role in synaptic plasticity and neuronal survival. They also enable the analysis of p90RSK signaling dysregulation in neurodegenerative disease models, uncovering potential links between p90RSK and neurological pathology.

Driving p90RSK-Targeted Drug Development

As a promising therapeutic target, p90RSK requires precision tools to support all stages of drug development, and p90RSK recombinant rabbit monoclonal antibodies play an indispensable role in inhibitor discovery and validation:

• Assay development for high-throughput screening: The antibodies are used to construct phosphorylation-specific ELISA assays for quantifying p90RSK kinase activity, enabling the high-throughput screening of small-molecule libraries to identify novel p90RSK inhibitors.
• Target engagement and efficacy evaluation: In cell-based and in vivo models, the antibodies correlate p90RSK inhibition (target engagement) with phenotypic effects (e.g., cell proliferation arrest, tumor growth inhibition), a critical step in validating lead compounds and optimizing inhibitor potency.
• In vivo efficacy and duration analysis: Immunohistochemical staining of tumor tissues from preclinical animal models with the antibodies evaluates the efficiency and duration of p90RSK inhibitor activity in vivo, and identifies off-target effects on the Ras-MAPK pathway.
• Combination therapy optimization: The antibodies detect the additive or synergistic inhibitory effects of p90RSK inhibitors with other anti-cancer drugs (e.g., chemotherapeutics, EGFR-TKIs) on p90RSK activation and downstream signaling, providing experimental evidence for developing rational combination therapy strategies.
• Drug resistance mechanism analysis: The antibodies track compensatory p90RSK signaling activation in drug-resistant cancer cells, enabling the identification of resistance mechanisms and guiding the design of next-generation p90RSK-targeted therapeutics.

p90RSK Antibodies in ANT BIO PTE. LTD.’s Research Ecosystem

As a leading provider of life science research reagents, ANT BIO PTE. LTD. leverages its Starter sub-brand—specialized in the development of high-performance recombinant antibodies—to engineer the p90RSK Recombinant Rabbit Monoclonal Antibody (S0B0782), a flagship reagent optimized for the multidimensional analysis of p90RSK kinase signaling. Developed via a mature recombinant rabbit monoclonal antibody platform (encompassing rational antigen design, epitope screening, single B-cell sorting, and multi-platform validation), this antibody embodies the precision and performance required for dissecting complex kinase signaling regulation, with core advantages including:

• Precise p90RSK family recognition: Targeting the conserved kinase domain of p90RSK via precise epitope screening, the antibody exhibits high-affinity recognition of all major p90RSK subtypes (RSK1-4) and excellent cross-species reactivity (human, mouse, rat), enabling comprehensive and specific detection of total p90RSK in diverse experimental systems.
• Exceptional affinity and low-background sensitivity: Engineered via the recombinant rabbit monoclonal platform, the antibody delivers high binding affinity and low non-specific background in all key applications, enabling the sensitive detection of low-abundance p90RSK and its phosphorylated forms in cell and tissue samples.
• Multi-platform versatility: Rigorously validated for use in Western Blot (WB), Immunoprecipitation (IP), Immunofluorescence (IF), Immunohistochemistry (IHC), and flow cytometry (Flow), the antibody adapts to all experimental techniques for p90RSK’s multidimensional analysis—eliminating the need for multiple reagents and streamlining research workflows.
• Superior batch-to-batch consistency: Produced via a recombinant expression system with a defined amino acid sequence, the antibody exhibits highly consistent performance across production batches, with stable physicochemical properties—providing reliable core reagents for long-term research projects, multi-center experiments, and translational drug development.

ANT BIO PTE. LTD. further supports researchers with comprehensive technical resources for the p90RSK Recombinant Rabbit Monoclonal Antibody (S0B0782), including subtype/species cross-reactivity validation data, optimized application protocols for all experimental platforms, and typical experimental results (e.g., FFPE tumor tissue IHC staining, immunofluorescence localization of nuclear p90RSK). Our professional technical team provides expert guidance for experimental design, Ras-MAPK/p90RSK signaling pathway analysis, cancer drug resistance research, and kinase-targeted drug development—empowering researchers to unlock the multidimensional regulation of kinase signaling and accelerate breakthroughs in basic and translational research.

Related Product List

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.

Disclaimer

This article was partially created with the assistance of artificial intelligence. If any content involves copyright or intellectual property issues, please inform us, and we promise to verify and remove it immediately.